AnaCardio announces positive scientific advice from the FDA and EMA, establishing a favourable development path for AC01 treatment of chronic HFrEF
Alignment reached with both the FDA and EMA on key elements of the AC01 development strategy in chronic HFrEF, allowing for a lean, straightforward and